- Home
- NBIX vs FMS Comparison
NBIX vs FMS Comparison
Compare NBIX & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | FMS |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 13.9B |
| IPO Year | 1996 | 1996 |
Fundamental Metrics
Financial Performance| Metric | NBIX | FMS |
|---|---|---|
| Price | $140.89 | $23.94 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 21 | 2 |
| Target Price | ★ $176.19 | $30.00 |
| AVG Volume (30 Days) | ★ 951.2K | 473.7K |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | ★ 12.44 | 8.62 |
| EPS | ★ 4.19 | 2.86 |
| Revenue | $2,682,700,000.00 | ★ $23,046,819,198.00 |
| Revenue This Year | $23.68 | $2.13 |
| Revenue Next Year | $18.47 | $2.95 |
| P/E Ratio | $34.27 | ★ $15.99 |
| Revenue Growth | ★ 19.61 | 2.10 |
| 52 Week Low | $84.23 | $22.05 |
| 52 Week High | $160.18 | $30.46 |
Technical Indicators
Market Signals| Indicator | NBIX | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 52.05 |
| Support Level | $141.00 | $23.83 |
| Resistance Level | $148.56 | $24.12 |
| Average True Range (ATR) | 3.93 | 0.25 |
| MACD | -1.13 | 0.12 |
| Stochastic Oscillator | 0.82 | 83.94 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.